🧬 Genetic Disorder

Dyskeratosis Congenita

Also known as: Zinsser-Cole-Engman Syndrome, DC

Dyskeratosis Congenita (DC) is a rare, inherited bone marrow failure syndrome characterized by the triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. It results from defects in telomere maintenance, leading to premature cellular senescence and a predisposition to bone marrow failure, pulmonary fibrosis, and cancer.

ICD-10: Q82.8 Orphanet: 235 OMIM: 127550
👥 1 in 1,000,000 Prevalence
🔬 25 Active Trials

Imagine your body's cells have tiny clocks called telomeres that get shorter each time they divide. Dyskeratosis Congenita is like having faulty clocks that run down too quickly. This causes problems with your skin, nails, mouth, and bone marrow, making it hard for your body to make new blood cells.

Signs & Symptoms

  • Abnormal skin pigmentation (reticular pigmentation, especially on the neck and upper chest)
  • Nail dystrophy (thin, brittle, or absent nails)
  • Oral leukoplakia (white patches in the mouth)
  • Bone marrow failure (leading to anemia, thrombocytopenia, and neutropenia)
  • Pulmonary fibrosis
  • Increased risk of cancer (especially squamous cell carcinoma and myelodysplastic syndrome/acute myeloid leukemia)
  • Developmental delay
  • Learning disabilities
  • Short stature
  • Liver disease
  • Gastrointestinal problems

Treatment Options

GENE THERAPY FDA Approved

Hematopoietic Stem Cell Transplantation (HSCT)

HIGHLY EFFECTIVE
MEDICATION FDA Approved

Androgens (Oxymetholone, Danazol)

MODERATELY EFFECTIVE
MEDICATION FDA Approved

Growth Factors (G-CSF, GM-CSF)

MODERATELY EFFECTIVE
MEDICATION FDA Approved

Immunosuppressive Therapy (Cyclosporine, Tacrolimus)

MODERATELY EFFECTIVE
SUPPORTIVE

Supportive Care (Blood transfusions, antibiotics, antifungals)

SUPPORTIVE
MEDICATION FDA Approved

Pulmonary Fibrosis Management (Pirfenidone, Nintedanib)

MODERATELY EFFECTIVE

Diagnosis

  • Clinical examination
  • Complete blood count (CBC)
  • Bone marrow aspiration and biopsy
  • Telomere length measurement (flow FISH)
  • Genetic testing (for mutations in genes associated with DC, such as TERT, TERC, DKC1, WRAP53, RTEL1)
  • Pulmonary function tests
  • Liver function tests
  • Skin biopsy

History

Dyskeratosis Congenita was first described in 1910 by Zinsser. Cole and Engman further characterized the syndrome in subsequent reports. The genetic basis of DC, involving telomere maintenance genes, was elucidated in the late 20th and early 21st centuries, leading to improved diagnostic and therapeutic strategies.

Recent Breakthroughs

2022

Novel Gene Therapies for Dyskeratosis Congenita

Research is underway to develop gene therapies that can correct the underlying genetic defects in DC, potentially offering a more curative approach than HSCT. Early preclinical studies have shown promise in restoring telomere function and improving hematopoietic function.

2023

Improved Telomere Length Measurement Techniques

Advancements in telomere length measurement techniques, such as improved flow FISH assays, have enhanced the accuracy and reliability of DC diagnosis, allowing for earlier detection and intervention.